Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
103.37
-2.46 (-2.32%)
Dec 26, 2025, 4:00 PM EST - Market closed
Palvella Therapeutics Employees
Palvella Therapeutics had 14 employees as of December 31, 2024.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,312,143
Market Cap
1.22B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PVLA News
- 5 days ago - Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst - Seeking Alpha
- 12 days ago - Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas - GlobeNewsWire
- 13 days ago - Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies - GlobeNewsWire
- 6 weeks ago - Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies - GlobeNewsWire
- 7 weeks ago - Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025 - GlobeNewsWire
- 2 months ago - U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations - GlobeNewsWire